血管腫治療の世界市場-2023年～2030年

市場概要

世界の血管腫治療市場は、2022年に2億8,460万米ドルに達し、2023～2030年の予測期間中にCAGR 3.8%で成長し、2030年には3億8,100万米ドルに達すると予測されています。

乳児血管腫は、新生児の約4％から5％を罹患する、乳児の間で最も一般的に発生する良性の血管腫瘍です。世界の血管腫治療市場は、β遮断薬治療の採用により近年著しい成長を遂げています。例えば、プロプラノロールやアテノロールは、乳児血管腫の治療薬として一般的に使用されているβ遮断薬です。

さらに、臨床試験の増加、投資の拡大、研究開発の増加といった重要な成長促進要因が、将来の市場成長をもたらしています。米国やカナダなどの国々における技術進歩の大幅な上昇により、市場は北米地域からの需要が増加しています。Akorn Pharmaceuticals社、Pfizer Inc.社、Alma Lasers Ltd.社、Allergan社などのその他の主要企業がこの市場で活発に活動しています。

ダイナミクス

市場促進要因

血管腫治療の技術的進歩の高まり

血管腫は、血管新生のプロセスを通じて毛細血管が増加する非がん性腫瘍であり、大手企業による主要な技術進歩が市場成長の原動力となっています。こうした効果的な進歩は、研究の発見を新たな治療法に変え、数十億人の血管腫患者の治療を改善するのに役立っています。

例えば、2020年9月、ピエール・ファーブル・ファーマシューティカルズは、治療の遅れに起因する合併症の回避に役立つ、乳児血管腫の早期診断と紹介のための新しいオンラインツールを報告しました。この研究は、乳児血管腫（IH）の早期診断、紹介、治療のための乳児血管腫紹介スコア（IHReS）の信頼性と使いやすさを強調しています。このように、上記の要因は予測期間における市場の成長を後押しします。

血管腫治療のための臨床試験の増加

血管腫の臨床試験は世界的に増加しており、血管腫治療市場の需要拡大の要因となっています。例えば、ClinicalTrial.govによると、2023年5月12日にインディアナ大学が血管腫の天然ベリーエキス治療に関する介入試験を実施しました。これは前向き無作為化二重盲検プラセボ対照並行群間比較試験です。

この臨床試験の目的は、修正妊娠月齢4ヵ月未満の乳児の血管腫の治療に対するペディアベリーの使用を6ヵ月の治療期間にわたって評価することです。治療にはペディアベリーが使用され、局所投与の場合はクリーム状のビヒクルと混合され、経口投与の場合は水と混合されます。

市場抑制要因

乳児血管腫に伴う合併症

乳児血管腫の合併症は、生命を脅かすもの、閉塞性のもの、潰瘍性のものに分類されます。生命を脅かす合併症には、気道および肝の乳児血管腫が含まれます。重要な構造を閉塞したり機能を損なったりする機能的合併症には、眼周囲、鼻腔、口唇、耳下腺、耳介および乳房の小児血管腫が含まれます。したがって、上記の要因により、予測期間中に市場は低迷すると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 血管腫治療の技術的進歩の高まり
    • 血管腫の臨床試験の増加
  • 抑制要因
    • 乳児血管腫に伴う合併症
  • 機会
    • 血管腫治療の新興市場
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 タイプ別

• 毛細血管腫
• 海綿状血管腫
• 複合血管腫
• 小葉状毛細血管腫

第9章 診断別

• 超音波検査
• CTスキャン
• MRI検査
• その他

第10章 治療別

• 薬物療法
• レーザー治療
• 手術
• β遮断薬
• その他

第11章 エンドユーザー別

• 病院
• 診療所
• 診断センター
• その他

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
    • アルゼンチン
    • その他南米
• アジア太平洋
  • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
• 中東・アフリカ

第13章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第14章 企業プロファイル

• Cutera Inc.
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Merck & Co.
• AbbVie Inc
• Akorn Pharmaceuticals
• Pfizer Inc.
• Alma Lasers ltd.
• Allergan
• Linline Medical Systems
• Pierre Fabre
• IRIDEX Corporation

第15章 企業概要付録

Market Overview

Global Hemangioma Treatment Market reached US$ 284.6 million in 2022 and is expected to reach US$ 381.0 million by 2030 growing with a CAGR of 3.8% during the forecast period 2023-2030.

Infantile hemangioma is the most commonly occurring benign vascular tumor among infants affecting about 4% to 5% of newborns. The global hemangioma treatment market has witnessed significant growth in recent years due to the adoption of beta-blocker treatments. For instance, propranolol and atenolol are beta blockers that are commonly used as a treatment for infantile hemangiomas.

Furthermore, significant growth drivers such as increasing clinical trials, growing investments, and increasing research and developments give rise to future market growth. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experiencing a rise in demand from North American regions. Significant key players like Akorn Pharmaceuticals, Pfizer Inc., Alma Lasers Ltd., Allergan, and others are actively operating in the market.

Dynamics

Market Drivers

Rising Technological Advancements for Hemangioma Treatment

Hemangiomas are non-cancerous tumors where capillary blood vessels increase in number through the process of angiogenesis, and the major technological advancements from major companies help to drive market growth. These effective advancements help to transform research discoveries into new treatments and improve care for billions of people with hemangiomas.

For instance, in September 2020, Pierre Fabre Pharmaceuticals reported a new online tool for the early diagnosis and referral of infantile hemangioma that can help avoid complications stemming from delayed treatment. This study highlights the reliability and ease of use of the Infantile Hemangioma Referral Score (IHReS) for the early diagnosis, referral, and treatment of infantile hemangioma (IH). Thus, the above factors help to boost the market growth in the forecast period.

The Increasing Clinical Trials for Hemangioma Treatment

The rising clinical trials of hemangioma globally act as the driver to the growing demand for the hemangioma treatment market. For instance, according to ClinicalTrial.gov, on May 12, 2023, Indiana University conducted an interventional study on Natural Berry Extract Treatment of Hemangiomas. This is a prospective, randomized, double-blind, placebo-controlled parallel-group study.

The aim of this clinical trial is to evaluate the use of PediaBerry for the treatment of hemangiomas in infants less than 4 months of corrected gestation age over a 6-month treatment period. The treatment involves PediaBerry which will be mixed with a cream vehicle for topical administration or with water for oral administration.

Market Restraints

Complications Associated with Infantile Hemangiomas

Infantile hemangioma complications are classified as life-threatening, obstructive, and ulcerative. Life-threatening complications include airway and hepatic infantile hemangiomas. Functional complications obstructing vital structures or impairing function involve periocular, nasal, labial, parotid, auricular, and breast infantile hemangiomas. Thus, owing to the above factors the market is expected to hamper over the forecast period.

Segment Analysis

The global hemangioma treatment market is segmented based on type, diagnosis, treatment, end users, and region.

Laser Therapy from the Treatment Segment Accounted for Approximately 38.5% of the Global Hemangioma Treatment Market Share

The rising clinical trials of hemangiomas globally have contributed to the growing demand for hemangioma treatment. Laser therapy involves the use of specific wavelengths of light to stimulate healing by allowing surgeons to work at high levels of precision by focusing on a small area by damaging less of the surrounding tissue. The main aim of performing laser therapy is to reduce inflammation and muscle pains.

For instance, according to clinicalTrials.gov, on August 12, 2022, Massachusetts General Hospital conducted a clinical trial on pulsed-dye laser versus timolol topical solution versus observation on the growth of hemangioma in newborn. The purpose of this study is to find out if pulsed dye laser treatment or timolol maleate 0.5% gel can help infants who have a hemangioma. Thus, the above factors help to elevate the market growth.

Geographical Penetration

North America Accounted for Approximately 38.9% of the Market Share in 2022

North America has maintained a significant proportion of the hemangioma market in recent years, and this trend is anticipated to continue throughout the forecast period due to the factors such as an increase in healthcare expenditures, increasing research and developments, and technological advancementsin hemangioma treatment.

For instance, according to the National Health Expenditure Account (NHEA), the total annual healthcare expenditure in the United States is increased by 2.7% to $4.3 trillion. Physician spending grew by an average of 3.5% per year while hospital services (4.4%) and clinical services (6.7%) had higher growth rates. Thus, the above factors help to elevate the region's growth.

Competitive Landscape

The major global players in the market include: Cutera Inc., Merck & Co., AbbVie Inc, Akorn Pharmaceuticals, Pfizer Inc., Alma Lasers Ltd., Allergan, Linline Medical Systems, Pierre Fabre, and IRIDEX Corporation among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the hemangioma treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in hemangioma treatment research. Clinical trials are vital for developing new treatments and improving outcomes in the hemangioma treatment market.

However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the hemangioma treatment market is expected to be moderately affected over the forecast period.

By Type

• Capillary Hemangioma
• Cavernous Hemangioma
• Compound Hemangioma
• Lobular Capillary Hemangioma

By Diagnosis

• Ultrasound
• MRI
• CT Scan
• Others

By Treatment

• Medical Therapy
• Laser Therapy
• Surgery
• Beta Blocker Medicines
• Others

By End Users

• Hospitals
• Clinics
• Diagnostic Centers
• Others

By Region

• North America

U.S.

Canada

Mexico

• Europe

Germany

U.K.

France

Italy

Spain

Rest of Europe

• South America

Brazil

Argentina

Rest of South America

• Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In June 2023, Candela Corporation announced that the Vbeam Family of Pulsed Dye Lasers (PDL) has expanded its FDA-cleared indications for use of the 595 nm wavelength to include the pediatric population for the treatment of cutaneous capillary malformations, also known as port wine stains (PWS), and infantile hemangiomas (IH) or congenital hemangiomas.
• In December 2021, research conducted led by the Centenary Institute and the Harvard Medical School, Boston, shows that a compound present in current beta blocker treatments could be repurposed to increase the efficiency and safety of infantile hemangioma therapies.
• In July 2023, the American Society for Laser Medicine and Surgery (ASLMS) worked with the Vascular Birthmarks Foundation (VBF) and an international, multidisciplinary team to create a consensus of uniform guidelines for treating vascular birthmarks with laser therapy.

Why Purchase the Report?

• To visualize the global hemangioma treatment market segmentation based on the type, diagnosis, treatment, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global hemangioma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hemangioma treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Diagnosis
• 3.3. Snippet by Treatment
• 3.4. Snippet by End Users
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising technological advancements for hemangioma treatment
    • 4.1.1.2. The increasing clinical trials for hemangioma
  • 4.1.2. Restraints
    • 4.1.2.1. Complications associated with infantile hemangiomas
  • 4.1.3. Opportunity
    • 4.1.3.1. Emerging markets of hemangioma treatments
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.1.2. Market Attractiveness Index, By Type
• 8.2. Capillary Hemangioma*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Cavernous Hemangioma
• 8.4. Compound Hemangioma
• 8.5. Lobular Capillary Hemangioma

9. By Diagnosis

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
  • 9.1.2. Market Attractiveness Index, By Diagnosis
• 9.2. Ultrasound*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. CT Scan
• 9.4. MRI
• 9.5. Others

10. By Treatment

• 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
• 10.1.2. Market Attractiveness Index, By Treatment
• 10.2. Medical Therapy
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Laser Therapy
• 10.4. Surgery
• 10.5. Beta Blocker Medicines
• 10.6. Others

11. By End Users

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 11.1.2. Market Attractiveness Index, By End Users
• 11.2. Hospitals*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Clinics
• 11.4. Diagnostic Centers
• 11.5. Others

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
  • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 12.2.7.1. U.S.
    • 12.2.7.2. Canada
    • 12.2.7.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
  • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 12.3.7.1. Germany
    • 12.3.7.2. U.K.
    • 12.3.7.3. France
    • 12.3.7.4. Italy
    • 12.3.7.5. Spain
    • 12.3.7.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
  • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  • 12.4.8. Brazil
    • 12.4.8.1. Argentina
    • 12.4.8.2. Rest of South America
• 12.5. Asia Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
  • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
  • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  • 12.5.8. China
    • 12.5.8.1. India
    • 12.5.8.2. Japan
    • 12.5.8.3. Australia
    • 12.5.8.4. Rest of Asia Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
  • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Cutera Inc.*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Merck & Co.
• 14.3. AbbVie Inc
• 14.4. Akorn Pharmaceuticals
• 14.5. Pfizer Inc.
• 14.6. Alma Lasers ltd.
• 14.7. Allergan
• 14.8. Linline Medical Systems
• 14.9. Pierre Fabre
• 14.10. IRIDEX Corporation

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us